Spectral Image Team

Douglas Lind joined Burrill & Company as a Managing Director in the Venture Group in January 2012. Previously he served as Managing Director at GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. He has more than 20 years experience in the life sciences industry, ranging from the practice of clinical medicine to work as a top tier Wall Street equity research analyst and venture capitalist. Throughout his career he has focused on identifying promising disruptive technologies and visionary leadership that offer high value solutions to pressing medical needs. He served as senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. His coverage of large and small capitalization biotechnology companies included Amgen, Biogen, Celera (acquired by Quest Diagnostics), Centocor (acquired by Johnson & Johnson), Chiron (acquired by Novartis), IDEC Pharmaceuticals (acquired by Biogen), ImClone (acquired by Bristol-Myers Squibb), MedImmune (acquired by AstraZeneca), Agouron (acquired by Warner Lambert), Axys Pharmaceuticals (acquired by Celera) and Millenium Pharmaceuticals (acquired by Takeda Pharmaceuticals). Dr. Lind is a graduate of the University of Iowa College of Medicine. He served as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed residency training in internal medicine. He currently serves on the board of directors of Lentigen, MabVax, TMune, HyperMed Imaging, and Spectral Image.

David Wetherell, Managing Partner at Burrill & Company, has spent more than 20 years as a CEO in high-tech, as well as 17 years in venture capital, the last seven of which have been dedicated to biotech and life sciences. From 1986 to 2006, he served as both CEO and, later, chairman of CMGI, where he helped build the company from $3 million in annual revenues to more than $1 billion and started the first venture capital firm focused on the Internet, @Ventures. When CMGI, now ModusLink, turned its direction away from the Internet to cleantech venture investing and supply chain management, Mr. Wetherell turned his attention to the life sciences industry. In 2005, he started GBP Capital, a venture capital company focused exclusively on leading edge life sciences. He has received numerous awards, including Ernst & Young's New England Entrepreneur of the Year in 2000 and recognition as one of Money Magazine’s Top 25 investors. He obtained his BA in Mathematics from Ohio Wesleyan University and an honorary doctorate from Bryant University. He currently serves as chairman of Lentigen and sits on the boards of numerous other companies, including HyperMed, Flexible Stenting Solutions, TMune Therapeutics and Quintess.